INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

Although the AERIFY-1 late-stage trial met the primary endpoint with a statistically significant and clinically meaningful impact, the AERIFY-2 trial failed to reach the same goal. On this news, Sanofi’s American Depositary Receipt (“ADR”) price fell $2.98 per ADR, or 5.69%, to close at $49.37 per ADR on May 30, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980